|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (AUPH, NASDAQ) |
Company Size: |
20-49 Employees In BC (20-49 Total)
20-49 In BC (20-49 Total)
|
Year Founded: |
2013 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Vancouver Island
Vancouver Island
|
Tags: |
Aurinia, biopharmaceutical, lupus, debilitating diseases
|
|
|
|
Reaching People, Changing Lives with Innovative Medications
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.
Our mission is to develop and deliver treatments to people suffering from debilitating diseases.
Leadership Backed by a Century of Industry Experience
Our highly skilled leadership team has a proven track record of success in targeted markets. Together they possess more than 100 years of combined corporate and industry specific experience. Our strategy leverages the skills and knowledge of our team's past clinical experience in the treatment of lupus. |
|
|
Date |
Type |
Amount |
Investors |
Dec 10, 2019 |
Unattributed |
$166.7 Million USD |
underwritten public offering of 11,115,165 common shares |
Jul 27, 2020 |
Unattributed |
$200 Million USD |
Public offering of 13,333,334 common shares. The shares were sold at a public offering price of US$15.00 per share |
Date |
Type |
Amount |
Investors |
Dec 10, 2019 |
Unattributed |
$166.7M USD |
underwritten public offering of 11,115,165 common shares |
Jul 27, 2020 |
Unattributed |
$200M USD |
Public offering of 13,333,334 common shares. The shares were sold at a public offering price of US$15.00 per share |
|
|
|
Want More Aurinia Pharmaceuticals Inc. News? 1 2 3 4
|
Next »
|
|
|
|
|
|
|
Aug 19, 2020
|
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
|
|
Aug 4, 2020
|
Victoria-based BioPharm Company Aurinia Announces U.S. FDA Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin
|
|
Jul 29, 2020
|
Victoria-based Aurinia Hauls in Another US$200 Million Financing (Public Offering of Common Shares)
|
|
Jun 23, 2020
|
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Solution for the Treatment of Dry Eye Syndrome
|
|
Jun 12, 2020
|
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
|
|
May 19, 2020
|
Aurinia Reports Strong Cash Position, Q1-2020 Financial Results and Recent Operational Highlights
|
|
Apr 28, 2020
|
Victoria-based Heavyweight Biopharm Company Aurinia Pharmaceuticals Appoints Joe Miller as Chief Financial Officer
|
|
Apr 20, 2020
|
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
|
|
Mar 19, 2020
|
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
|
|
Mar 17, 2020
|
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin
|
|
|
1 - 10 of 39 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
